| CRARX | CSEIX | CRARX / CSEIX | |
| Total Expense Ratio | 0.83 | 1.10 | 75% |
| Annual Report Gross Expense Ratio | 1.14 | 1.10 | 104% |
| Fund Existence | 29 years | 29 years | - |
| Gain YTD | 12.419 | 10.308 | 120% |
| Front Load | N/A | 5% | - |
| Min. Initial Investment | 1000000 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 217M | 9.52B | 2% |
| Annual Yield % from dividends | 2.20 | 2.78 | 79% |
| Returns for 1 year | 11.09 | 10.10 | 110% |
| Returns for 3 years | 26.38 | 34.05 | 77% |
| Returns for 5 years | -12.71 | 9.43 | -135% |
| Returns for 10 years | -28.47 | 60.11 | -47% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ITDJ | 33.06 | 0.15 | +0.45% |
| iShares LifePath Target Date 2070 ETF | |||
| IWMW | 38.45 | 0.11 | +0.29% |
| iShares Russell 2000 BuyWrite ETF | |||
| CBTA | 22.10 | N/A | N/A |
| Calamos Bitcoin 80 Series Structured Alt Protection ETF - April | |||
| BUFD | 29.70 | -0.02 | -0.07% |
| FT Vest Laddered Deep Buffer ETF | |||
| PBE | 80.89 | -1.84 | -2.22% |
| Invesco Biotechnology & Genome ETF | |||